OncoResponse is focused on developing innovative cancer immunotherapies by harnessing the immune responses of patients who have shown exceptional reactions to cancer treatments, particularly immune checkpoint inhibitors (CPI). The company employs a proprietary technology platform that enables the identification of human antibodies from the immune systems of these "Elite Responders." This platform allows for the rapid screening of a vast array of antibodies, specifically targeting immunosuppressive myeloid biology within the tumor microenvironment (TME). By isolating antibodies that can reverse the immunosuppressive effects of the TME, OncoResponse aims to enhance the efficacy of existing immunotherapies and convert "cold" tumors into "hot" tumors, thereby improving patient outcomes.

The company’s pipeline includes a range of monoclonal antibodies designed to alleviate immunosuppression in the TME, with a particular focus on reprogramming tumor-associated macrophages (TAMs) from a pro-tumor M2-like phenotype to a more favorable M1-like state. This reprogramming is crucial, as M2 TAMs are known to inhibit anti-tumor T-cell activity and contribute to resistance against CPI therapies. OncoResponse's lead antibody, OR2805, exemplifies this approach by specifically targeting M2-like TAMs, promoting T-cell activation and proliferation, and ultimately enhancing the clinical responses to immunotherapy. Through strategic collaborations, such as with MD Anderson Cancer Center, OncoResponse is advancing its research and clinical studies across various tumor types, aiming to deliver more effective cancer treatments.

United States

OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology.OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.

OncoResponse

Company Details